Overview

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.
Phase:
Phase 3
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Acyclovir